Andrew Sinclair

Partner · Abingworth

Decision makerActive

Email

Verified, deliverable email

Unlock Andrew and the rest of Abingworth

One payment, no subscription - every verified contact at Abingworth drops into your wallet.

Partner, Portfolio Manager at Abingworth

Stages: Series A, Seed
Sectors: Health tech
Cheque size: €13.8M–€27.6M
Freshness: Verified today
Fund size: $465M

Notable investments

R1 TherapeuticsSeries A · $78M · 2026
Ascend Gene & Cell TherapiesSeries A · $66M · 2023
Entact BioSeries A · $81M · 2022
Soleno TherapeuticsPost Ipo Equity · $17M · 2018

Frequently co-invests with

Andrew Kozlov4BIO CapitalBali MuralidharAbingworthBen AuspitzForge Life Science PartnersChong XuF-Prime Capital PartnersEric Shiozaki (DCVC (Data Collective))Jack SchulerOwen Smith4BIO CapitalRichard GastervenBio

Background

Partner, Portfolio ManagerAbingworth2008–present

Andrew Sinclair's colleagues at Abingworth

Every verified colleague at Abingworth

One payment, no subscription - they all drop into your wallet.

Genghis Lloyd-HarrisPartner, Abingworth

Kurt von EmsterManaging Partner, Abingworth

Jacqueline GrantPrincipal, Abingworth

See all 4 at Abingworth →

Related lists

Health tech investors

Similar investors

Quan ZhouManaging Partner, IDG Capital

Raffi KamberGeneral Partner, Singular

Blake PateAnalyst, Bios Partners

Przemek OblojManaging Partner, Blue Horizon

Prashant NarangPartner, Fluid Ventures

Prachi SinhaInvestor, Axilor Ventures

Every contact is a verified, deliverable email. How Mintround verifies contacts.

Are you Andrew Sinclair? Request removal of this listing.